Søgning
Søgning på udtrykket 'paxlovid' giver 11 resultater
Dokumenter [1] Nyt fra tidsskrifterne [6] Aktuelle smitsomme sygdomme [4]
Dokumenter [1]
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Ændringer siden version 29: Indikationer for COVID-19 test er tilføjet.
Nyt fra tidsskrifterne [6]
BMJ Open
28. juni 2025
[…] and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing hypertension. The objective of this study was to assess their effectiveness and safety among those patients in a real-world context. DesignRetrospective cohort study. SettingElectronic medical record data of COVID-19 patients with pre-existing hypertension were […]
Journal of Medical Virology
16. april 2025
Journal of Medical Virology, Volume 97, Issue 4, April 2025.
BMC Infectious Diseases
1. marts 2025
[…] patients with KD remain unknown. Methods This study included 32,864 COVID-19 patients from nine centers in Henan Province, China. After applying the exclusion criteria and 2:1 propensity score matching, 438 and 219 participants in the Azvudine and Paxlovid groups, respectively, were subjected to analysis. Results Kaplan–Meier analysis revealed no significant differences in all-cause death or composite disease progression between the Azvudine and Paxlovid groups (all p values > 0.05). The same […]
BMC Infectious Diseases
26. november 2024
[…] Background Paxlovid is one of the most effective antiviral therapies for COVID-19 patients, but no studies have explored the efficacy predictors of this drug. Methods To investigate whether D-dimer could be used as a predictor of paxlovid response. Our study included 394 patients diagnosed with COVID-19 who were treated with paxlovid at Xiangya Hospital from Dec 5, 2022, to Jan 31, 2023. We analyzed the composite outcome and all-cause mortality and compared the clinical and demographic data of […]
BMJ Open
4. august 2025
[…] to receive either usual care, including supportive and symptom-based management, or an investigational therapeutic selected by the Canadian COVID-19 Outpatient Therapeutics Committee. The first therapeutic arm evaluates nirmatrelvir/ritonavir (Paxlovid), administered two times per day for 5 days. The second therapeutic arm investigates a combination antioxidant therapy (selenium 300 µg, zinc 40 mg, lycopene 45 mg and vitamin C 1.5 g), administered for 10 days. The primary outcome is all-cause […]
Clinical Infectious Diseases
18. december 2024
[…] Background PAXLOVID consists of nirmatrelvir, an inhibitor of SARS-CoV-2 main protease (Mpro), copackaged with ritonavir, a pharmacokinetic enhancer. Nirmatrelvir/ritonavir received emergency use authorization in the United States in 2021 and was approved in 2023. However, there is limited published information on SARS-CoV-2 clinical resistance to nirmatrelvir/ritonavir.Methods To investigate SARS-CoV-2 resistance development to nirmatrelvir/ritonavir in treated patients, we analyzed baseline and […]
Aktuelle smitsomme sygdomme [4]
Aktuelle smitsomme sygdomme [4]
Medscape Infectious Diseases
26. februar 2025
Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of COVID-19–related hospital admissions or deaths. Medscape Medical News
Medscape Infectious Diseases
1. februar 2025
New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are preliminary but promising. Medscape Medical News
Medscape Infectious Diseases
10. juli 2025
A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to-moderate COVID-19 with moderate certainty. Medscape Medical News
Medscape Infectious Diseases
1. januar 2025
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb\'s cancer cell therapies and... Reuters Health Information